Indian Council of Medical Research, Scientist and Head of Epidemiology and Communicable Diseases Division, Dr. Samiran Panda while speaking to ANI assured that both Covishield and Covaxin are safe and there should not be an iota of apprehension about its safety.
"Both Covishield and Covaxin are safe and there should not be an iota of apprehension about its safety.
We should all try to dispel the myths and misconceptions around both vaccines." Further appreciating India's scientists, Panda said, "In older days, it would take 20-30 yrs to get a vaccine or medicine out in market.
Since knowledge about the whole genome of virus, within10-12 months the vaccine (Covaxin) has come out and it underlines the superiority, ability and commitment of Indian scientists."
Fire broke out at Manjri facility of Pune’s Serum Institute of India on Thursday. Pune’s Mayor Murlidhar Mohol said that a call was received at 2.50pm. Reportedly, ten fire tenders were rushed to the spot along with at least two extra tankers. As per reports, fire was reported from the fifth floor of the recently constructed building. Smoke was seen coming out of the building. Serum Institute of India is manufacturing coronavirus vaccine Covishield. Watch the full video for more details.
Credit: HT Digital Content Duration: 01:31Published
India on Wednesday sent coronavirus vaccines to Bhutan and Maldives. India is sending doses of the Covishield vaccine. Trucks with Covishield left from Pune’s Serum Institute of India for Bhutan. The move is in keeping with India’s “neighborhood first” policy. Consignments were airlifted and handed over to officials in Maldives and Bhutan. India will also be dispatching vaccines to Bangladesh, Nepal, Myanmar, and Seychelles. This comes days after India launched the Covid-19 vaccination drive on January 16. Watch the full video for more details.
Credit: HT Digital Content Duration: 02:26Published
Union Health minister Dr. Harsh Vardhan reiterated the two vaccines which have been granted approval for use in India are safe and effective. He added that some people are playing politics over the issue resulting in vaccine hesitancy among a section of the people. Harsh Vardhan said that the vaccines will be the last nail in the coffin of Covid. He also said that mild fever, pain and swelling are common after vaccination and added that very few people have shown these side-effects too. Questions have been raised about the safety of Covaxin which has not yet published any data from phase three clinical trials. Additionally, the government has also said that people will not get to choose a vaccine in the first phase. Watch the full video for all the details.
Credit: HT Digital Content Duration: 03:11Published
Health and Family Welfare Ministry of India on January 19 said that in case of the Covaxin which has been given emergency use authorization under clinical trial mode (Covaxin), hospitalization cost would be borne by authorities. He said, "There are two vaccines. One of the two vaccines is given emergency use authorization under clinical trial mode. In a document for this vaccine, it's mentioned that if there's causal relation between immunization and adverse event weather it is severe or serious, hospitalization cost would be borne by authorities."
Karnataka Association of Resident Doctors (KARD) has demanded the government to let people choose which COVID-19 vaccine, between Pune-based Serum Institute of India's Covishield and Hyderabad-based Bharat Biotech's Covaxin, they want to take. "Government of India has approved Covishield and Covaxin vaccines. We have all the reports for Covishield. But, Covaxin is still in phase-III trials, where the trial is being done on healthcare workers. We condemn this...Healthcare workers should be given a choice of vaccine," said Dr Dayanand Sagar. GoI rolled out COVID-19 vaccine jab from January 16.
As per the data released by Ministry of Health and Family Welfare (MoHFW), India on January 19 reported single-day spike of 10,064 new coronavirus cases in the last 24 hours. 137 deaths in the same period pushed the COVID-19 toll in the country to 1,52,556. India's confirmed cases of coronavirus stand at 1,05,81,837 which include 2,00,528 active infections. More than 1,02,28,753 people have recovered from the virus with 17,411 new discharges in last 24 hours. According to Indian Council of Medical Research (ICMR), a total of 7,09,791 samples were tested on January 18. Cumulative samples tested for COVID-19 till January 18 are 18,78,02,827.
As per the data released by Ministry of Health and Family Welfare (MoHFW), India on January 18 reported single-day spike of 13,788 new coronavirus cases in the last 24 hours. 145 deaths in the same period pushed the COVID-19 toll in the country to 1,52,419. India's confirmed cases of coronavirus stand at 1,05,71,773 which include 2,08,012 active infections. More than 1,02,11,342 people have recovered from the virus with 14,457 new discharges in last 24 hours. According to Indian Council of Medical Research (ICMR), a total of 5,48,168 samples were tested on January 17. Cumulative samples tested for COVID-19 till January 17 are 18,70,93,036.
On January 16, total COVID-19 tally of India reached to 1,05,42,841. The country reported 15,158 new COVID-19 cases in last 24 hours and active cases stands at 2,11,033. With new 16,977 discharges, total number reached to 1,01,79715. 175 deaths were reported in last 24 hours, taking cumulative toll to 1,52,093. According to ICMR, total number of samples tested up to 11th January is 18,57,65,491 and of these, 8,03,090 samples were tested yesterday.